Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2014

Open Access 01-12-2014 | Research article

The prevalence of dyslipidemia in patients with diabetes mellitus of ayurveda Hospital

Authors: Amit Kumar Dixit, Ranjit Dey, Aela Suresh, Siddhartha Chaudhuri, Ashok Kumar Panda, Achintya Mitra, Jayram Hazra

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2014

Login to get access

Abstract

Background

Dyslipidemia is one of the major risk factors for cardiovascular disease in diabetes mellitus. Early detection and treatment of dyslipidemia in type-2 diabetes mellitus can prevent risk for atherogenic cardiovascular disorder. The rationale of this study was to detect the lipid abnormality in diabetic patients.

Methods

Necessary data was collected from the medical archives of 150 patients (73 female and 77 male) with diabetes mellitus registered in Department of pathology and biochemistry of a Ayurveda hospital established at Kolkata, India.

Results

The mean ages of female and male subjects were 51.8 ± 10.8 and 53.2 ± 11.3 years respectively. The range and mean value of FBS in females were 113–342 mg/dl and 157.7 ± 6.3 mg/dl, while the range and mean value of PPBS in females were 135–560 mg/dl and 275.5 ± 12.3 mg/dl respectively. Results showed that range and mean value of FBS in males were 111–462 mg/dl and 160.8 ± 7.4 mg/dl, while the range and mean value of PPBS in males were 136–598 mg/dl and 302.1 ± 12.6 mg/dl respectively. Results of serum lipids showed that the mean values for total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and very low density lipoprotein cholesterol (VLDL-C) in female patients were 202.2 ± 5.9 mg/dl, 168.3 ± 8.2 mg/dl, 44.9 ± 1.3 mg/dl, 123.6 ± 5.2 mg/dl and 33.7 ± 1.7 mg/dl respectively. The mean values for TC, TG, HDL-C, LDL-C and VLDL-C in male patients were 182.5 ± 4.8 mg/dl, 128.1 ± 10.8 mg/dl, 40.8 ± 1.2 mg/dl, 105.4 ± 4.8 mg/dl and 36.2 ± 2.2 respectively. FBS showed significant positive correlation with PPBS, cholesterol, TG, and VLDL-C. PPBS also demonstrated direct and significant correlations with TG and VLDL-C.

Conclusions

The study showed common lipid abnormalities during diabetes induced dyslipidemia i.e., hypercholesterolemia, hypertriglyceridemia and elevated LDL-C. This study suggests the dominance of hyperlipidemia over increased prevalence of dyslipidemia.
Literature
1.
go back to reference Uttra KM, Devrajani BR, Shah SZA, Devrajani T, Das T, Raza S, Naseem : Lipid profile of patients with diabetes mellitus (A Multidisciplinary Study). World Appl Sci J 2011, 12(9):1382–1384. Uttra KM, Devrajani BR, Shah SZA, Devrajani T, Das T, Raza S, Naseem : Lipid profile of patients with diabetes mellitus (A Multidisciplinary Study). World Appl Sci J 2011, 12(9):1382–1384.
2.
go back to reference Abou-Seif MA, Youssef AA: Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 2004, 346: 161–170. 10.1016/j.cccn.2004.03.030CrossRefPubMed Abou-Seif MA, Youssef AA: Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 2004, 346: 161–170. 10.1016/j.cccn.2004.03.030CrossRefPubMed
3.
go back to reference Roberto T, Dodesini AR, Lepore G: Lipid and Renal disease. J Am Soc Nephrol 2006, 17: S145-S147. 10.1681/ASN.2005121320CrossRef Roberto T, Dodesini AR, Lepore G: Lipid and Renal disease. J Am Soc Nephrol 2006, 17: S145-S147. 10.1681/ASN.2005121320CrossRef
4.
go back to reference Elinasri HA, Ahmed AM: Patterns of lipid changes among type 2 diabetes patients in Sudan. Eastern Mediter Health J 2008, 14: 2. Elinasri HA, Ahmed AM: Patterns of lipid changes among type 2 diabetes patients in Sudan. Eastern Mediter Health J 2008, 14: 2.
5.
go back to reference Mooradian AD: Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrin Metab 2009, 5: 150–159. 10.1038/ncpendmet1066 Mooradian AD: Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrin Metab 2009, 5: 150–159. 10.1038/ncpendmet1066
6.
go back to reference Goldberg IJ: Diabetic dyslipidemia: causes and consequences. J Clin Endo Metab 2001, 8(3):965–971.CrossRef Goldberg IJ: Diabetic dyslipidemia: causes and consequences. J Clin Endo Metab 2001, 8(3):965–971.CrossRef
7.
go back to reference Smith S, Lall AM: A Study on lipid profile levels of diabetics and non-diabetics among Naini region of Allahabad. India Turkish J Biochem 2008, 33(4):138–141. Smith S, Lall AM: A Study on lipid profile levels of diabetics and non-diabetics among Naini region of Allahabad. India Turkish J Biochem 2008, 33(4):138–141.
8.
go back to reference Taskinen MR: Diabetic dyslipidemia. Atheroscler Suppl 2002, 3(1):47–51. 10.1016/S1567-5688(01)00006-XCrossRefPubMed Taskinen MR: Diabetic dyslipidemia. Atheroscler Suppl 2002, 3(1):47–51. 10.1016/S1567-5688(01)00006-XCrossRefPubMed
9.
go back to reference Mahato RV, Gyawali P, Raut PP, Regmi P, Singh PK, Pandey DR, Gyawali P: Association between glycaemic control and serum lipid profile in type 2 diabetic patients: glycated haemoglobin as a dual biomarker. Biomed Res 2011, 22(3):375–380. Mahato RV, Gyawali P, Raut PP, Regmi P, Singh PK, Pandey DR, Gyawali P: Association between glycaemic control and serum lipid profile in type 2 diabetic patients: glycated haemoglobin as a dual biomarker. Biomed Res 2011, 22(3):375–380.
10.
go back to reference Wexler DJ, Grant RW, Meigs JB, Nathan DM: Cagliero: sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005, 28: 514–520. 10.2337/diacare.28.3.514CrossRefPubMed Wexler DJ, Grant RW, Meigs JB, Nathan DM: Cagliero: sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care 2005, 28: 514–520. 10.2337/diacare.28.3.514CrossRefPubMed
11.
go back to reference Regmi P, Gyawali P, Shrestha R, Sigdel M, Mehta KD, Majhi S: Pattern of Dyslipidemia in Type-2 Diabetic Subjects in Eastern Nepal. J Nepal Assoc Med Lab Sci 2009, 10: 11–13. Regmi P, Gyawali P, Shrestha R, Sigdel M, Mehta KD, Majhi S: Pattern of Dyslipidemia in Type-2 Diabetic Subjects in Eastern Nepal. J Nepal Assoc Med Lab Sci 2009, 10: 11–13.
12.
go back to reference Peters AL: Clinical relevance of non-HDL cholesterol in patients with diabetes. Clin Diabetes 2008, 26: 3–7. 10.2337/diaclin.26.1.3CrossRef Peters AL: Clinical relevance of non-HDL cholesterol in patients with diabetes. Clin Diabetes 2008, 26: 3–7. 10.2337/diaclin.26.1.3CrossRef
13.
go back to reference Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ: Non-HDL cholesterol as a predictor of cardiovascular disease in type-2 diabetes: the strong heart study. Diabetes Care 2003, 26: 16–23. 10.2337/diacare.26.1.16CrossRefPubMed Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ: Non-HDL cholesterol as a predictor of cardiovascular disease in type-2 diabetes: the strong heart study. Diabetes Care 2003, 26: 16–23. 10.2337/diacare.26.1.16CrossRefPubMed
14.
go back to reference Chatterjee MN, Shinde R: Text book of medical laboratory technology. Metabolism of carbohydrates. 6th edition. Delhi-India: Jaypee Brothers Medical publisher; 2005:266–330. Chatterjee MN, Shinde R: Text book of medical laboratory technology. Metabolism of carbohydrates. 6th edition. Delhi-India: Jaypee Brothers Medical publisher; 2005:266–330.
15.
go back to reference Haffner SM, Mykkanen L, Festa A: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Circulation 2000, 101: 975–980. 10.1161/01.CIR.101.9.975CrossRefPubMed Haffner SM, Mykkanen L, Festa A: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Circulation 2000, 101: 975–980. 10.1161/01.CIR.101.9.975CrossRefPubMed
16.
go back to reference Nau DP, Mallya U: Sex disparity in the management of dyslipidemia among patients with type 2 diabetes mellitus in a managed care organization. Am J Manag Care 2005, 11: 69–73.PubMed Nau DP, Mallya U: Sex disparity in the management of dyslipidemia among patients with type 2 diabetes mellitus in a managed care organization. Am J Manag Care 2005, 11: 69–73.PubMed
17.
go back to reference Abbate SL, Brunzell JD: Pathophysiology of hyperlipidemia in diabetes. J Cardiovasc Pharmacol 1990, 16: 1–7.CrossRef Abbate SL, Brunzell JD: Pathophysiology of hyperlipidemia in diabetes. J Cardiovasc Pharmacol 1990, 16: 1–7.CrossRef
18.
go back to reference Packard C, Nunn A, Hobbs R: High density lipoprotein: guardian of the vascular system. Inter J Clin Pract 2002, 56: 761–771. Packard C, Nunn A, Hobbs R: High density lipoprotein: guardian of the vascular system. Inter J Clin Pract 2002, 56: 761–771.
19.
go back to reference Sparks JD, Sparks CE: Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes. J Biol Chem 1990, 265(15):8854–8862.CrossRefPubMed Sparks JD, Sparks CE: Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes. J Biol Chem 1990, 265(15):8854–8862.CrossRefPubMed
20.
go back to reference Rosediani M, Azidah AK, Mafauzy M: Correlation between fasting plasma glucose, post prandial glucose and glycated haemoglobin and fructosamine. Med J Malays 2006, 61: 67–71. Rosediani M, Azidah AK, Mafauzy M: Correlation between fasting plasma glucose, post prandial glucose and glycated haemoglobin and fructosamine. Med J Malays 2006, 61: 67–71.
21.
go back to reference Tseng CH: Lipid abnormalities associated with urinary albumin excretion rate in Taiwanese type 2 diabetic patients. Kid Inter 2005, 67: 1547–1553. 10.1111/j.1523-1755.2005.00235.xCrossRef Tseng CH: Lipid abnormalities associated with urinary albumin excretion rate in Taiwanese type 2 diabetic patients. Kid Inter 2005, 67: 1547–1553. 10.1111/j.1523-1755.2005.00235.xCrossRef
22.
go back to reference Tseng CH: Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kid Inter 2005, 68: 796–801. 10.1111/j.1523-1755.2005.00459.xCrossRef Tseng CH: Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kid Inter 2005, 68: 796–801. 10.1111/j.1523-1755.2005.00459.xCrossRef
23.
go back to reference Gimeno-Orna JA, Faure-Nogueras E, Sancho-Serrano MA: Usefulness of total cholesterol/HDL-cholesterol ratio in the management of diabetic dyslipidemia. Diabetes Med 2005, 22: 26–31.CrossRef Gimeno-Orna JA, Faure-Nogueras E, Sancho-Serrano MA: Usefulness of total cholesterol/HDL-cholesterol ratio in the management of diabetic dyslipidemia. Diabetes Med 2005, 22: 26–31.CrossRef
24.
go back to reference Andersen GE, Christiansen JS, Mortensen HB, Christiansen KM, Predersen-Bjerguard L, Kastrup KW: Plasma lipid and lipoprotein in type 1 diabetic children and adolescent in relation to metabolic regulation, obesity and genetic hyperlipoprotenimia. Acta Paediatr Scand 1983, 72: 361–365. 10.1111/j.1651-2227.1983.tb09729.xCrossRefPubMed Andersen GE, Christiansen JS, Mortensen HB, Christiansen KM, Predersen-Bjerguard L, Kastrup KW: Plasma lipid and lipoprotein in type 1 diabetic children and adolescent in relation to metabolic regulation, obesity and genetic hyperlipoprotenimia. Acta Paediatr Scand 1983, 72: 361–365. 10.1111/j.1651-2227.1983.tb09729.xCrossRefPubMed
25.
go back to reference Hachem SB, Mooradian AD: Familial dyslipidaemias: an overview of genetics, pathophysiology and management. Drugs 2006, 66: 1949–1969. 10.2165/00003495-200666150-00005CrossRefPubMed Hachem SB, Mooradian AD: Familial dyslipidaemias: an overview of genetics, pathophysiology and management. Drugs 2006, 66: 1949–1969. 10.2165/00003495-200666150-00005CrossRefPubMed
26.
go back to reference Siraj ES, Seyoun B, Saenz C, Abdulkadir J: Lipid and lipoprotein profil;e in Ethopian patients with diabetes mellitus. Metabolism 2006, 55: 706–710. 10.1016/j.metabol.2005.08.002CrossRefPubMed Siraj ES, Seyoun B, Saenz C, Abdulkadir J: Lipid and lipoprotein profil;e in Ethopian patients with diabetes mellitus. Metabolism 2006, 55: 706–710. 10.1016/j.metabol.2005.08.002CrossRefPubMed
27.
go back to reference Al-Habori M, Al-Mamari M, Al-Meeri A: Type II diabetes mellitus and impaired glucose tolerance in Yemen: frequency, associated metabolic changes and risk factors. Diabetes Res Clin Pract 2004, 65: 275–281. 10.1016/j.diabres.2004.02.001CrossRefPubMed Al-Habori M, Al-Mamari M, Al-Meeri A: Type II diabetes mellitus and impaired glucose tolerance in Yemen: frequency, associated metabolic changes and risk factors. Diabetes Res Clin Pract 2004, 65: 275–281. 10.1016/j.diabres.2004.02.001CrossRefPubMed
Metadata
Title
The prevalence of dyslipidemia in patients with diabetes mellitus of ayurveda Hospital
Authors
Amit Kumar Dixit
Ranjit Dey
Aela Suresh
Siddhartha Chaudhuri
Ashok Kumar Panda
Achintya Mitra
Jayram Hazra
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2014
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1186/2251-6581-13-58

Other articles of this Issue 1/2014

Journal of Diabetes & Metabolic Disorders 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine